NCT06216847 Clinical Outcomes of Patients With Coronary Artery Disease
| NCT ID | NCT06216847 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shenyang Northern Hospital |
| Condition | Coronary Heart Disease (CHD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2024-02-21 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2024-02-21 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Coronary heart disease (CHD) stands as a foremost contributor to global mortality, characterized by complex pathogenesis that renders conventional "one-size-fits-all" preventive strategies inefficient. Therefore, the investigators designed a prospective, multi-center cohort study among patients hospitalized due to either confirmed or suspected CHD, which aimed to establish a holographic data set for the diagnosis and treatment of CHD and explore the impact of critical therapeutic strategies in the real world on the clinical outcomes of CHD patients, providing evidence to optimize the management pathway.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * Hospitalization due to either confirmed or suspected CHD combined with one of the following features: previous PCI or CABG; previous myocardial infarction; previous coronary angiography revealing ≥ 50% stenosis in major coronary vessels; presentation with chest pain and pre-test probability of CHD \> 65%; laboratory tests revealing objective evidence of myocardial ischemia; coronary CT angiography (CTA) showed ≥ 30% stenosis in major coronary vessels * Subjects undergoing at least one coronary imaging and one functional examination. Imaging examinations include coronary CTA, intravascular ultrasound (IVUS), or optical coherence tomography (OCT). Functional examination include fraction flow reservation (FFR), CT-FFR or quantitative flow ratio (QFR). * Written informed consent provided. Exclusion Criteria: * History of mental illness, drug or alcohol abuse, or being unable to cooperate with follow-up visits for any reason; * Life expectancy \<1 year * Pregnant or plan to be pregnant within 1 year * Subjects participating in any other clinical trial * Other conditions deemed unsuitable for inclusion by the investigator
Contact & Investigator
Yaling Han, MD
PRINCIPAL INVESTIGATOR
The General Hospital of Northern Theater Command
Frequently Asked Questions
Who can join the NCT06216847 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Heart Disease (CHD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06216847 currently recruiting?
Yes, NCT06216847 is actively recruiting participants. Contact the research team at doctorliyi@126.com for enrollment information.
Where is the NCT06216847 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT06216847 clinical trial?
NCT06216847 is sponsored by Shenyang Northern Hospital. The principal investigator is Yaling Han, MD at The General Hospital of Northern Theater Command. The trial plans to enroll 10,000 participants.